57 results about "Inflammatory dermatosis" patented technology

The present disclosure provides methods of treating an inflammatory skin disease (e.g., psoriasis) in a subject by administering an inhibitor of Hypoxia Inducible Factor 1α (HIF1α) or an inhibitor of glucose transporter 1 (Glut1). The present disclosure also provides topical formulations comprising an inhibitor of HIF1α or an inhibitor of Glut1.

An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

The invention belongs to the technical field of microorganisms, and particularly relates to a staphylococcus epidermidis H62-3 metabolite gel preparation as well as a preparation method and application thereof. The staphylococcus epidermidis H62-3 metabolite gel preparation improves skin erythema and scale symptoms of a psoriasis mouse model, remarkably reduces the skin lesion thickness, can reduce the mRNA expression level of inflammatory factors interleukin-17A, interleukin-17F and interleukin-23 at the skin lesion of the psoriasis mouse model, and can be used for treating psoriasis. The compound has a prospect of being developed into drugs for treating inflammatory dermatosis. The staphylococcus epidermidis H62-3 metabolite gel preparation disclosed by the invention is used for improving a psoriasis mouse model, and a new thought for safely and effectively treating inflammatory skin diseases by external use of viable bacteria metabolite is provided.

Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.075 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, aerosol spray, non-aerosol spray,, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and / or reduction in itchiness, and hot or burning sensation in the affected area compared to pre-treatment levels.

Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.075 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, aerosol spray, non-aerosol spray,, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and / or reduction in itchiness, and hot or burning sensation in the affected area compared to pre-treatment levels.

Provided herein are pharmaceutical formulations comprising an optionally 4-substituted phenylbutyrate for improved topical application. In some embodiments, the optionally 4-substituted phenylbutyrate is present at a concentration ranging from about 1-40% by weight. The present disclosure also provides methods of preparing said pharmaceutical formulations, as well as uses and methods of treating subjects affected by inflammatory skin disorder or skin-related disease with said pharmaceutical formulations.

The invention provides a pharmaceutical composition for treating inflammatory skin diseases, and particularly relates to an O / W cream containing trifarotene. The pharmaceutical composition provided by the invention has proper viscosity and elasticity, and the trifarotene composition preferably contains diethylene glycol monoethyl ether. The pharmaceutical composition can be directly applied to skin.

The present disclosure provides methods of treating an inflammatory skin disease (e g., psoriasis) in a subject by administering an inhibitor of Hypoxia Inducible Factor la (HIFla) or an inhibitor of glucose transporter 1 (Glut!). The present disclosure also provides topical formulations comprising an inhibitor of HIFla or an inhibitor of Glutl.

The present invention relates to an inhibitor of CD74 protein activity or expression, for the therapeutic use thereof in the prevention and / or treatment of chronic inflammatory diseases including: chronic inflammatory rheumatisms, chronic inflammatory dermatoses, chronic inflammatory bowel diseases and chronic inflammatory neurological diseases. In another embodiment, the invention relates to an isolated anti-CD74 antibody or fragment thereof, comprising six CDRs having the sequences SEQ ID NO. 3, 4, 5, 11, 12, and 13.

The present invention relates to a novel ALPK1 inhibitor of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, stable isotope variant, prodrug or crystalline form thereof. The invention also relates to pharmaceutical compositions comprising said novel ALPK1 inhibitors and their use in the treatment of inflammatory related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including Alzheimer's disease. # imgabs0 #

The present disclosure relates to a novel ALPK1 inhibitor of formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, atropisomer, stable isotope variant, prodrug, or crystalline form thereof. The disclosure also relates to pharmaceutical compositions comprising said novel ALPK1 inhibitors, and their use in the treatment of inflammatory related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin disease, and neurodegenerative diseases including Alzheimer's disease.

The invention relates to a novel disulfide diphenol ether compound and a preparation method and application thereof in the aspect of treating inflammatory dermatosis, the structural formula of the disulfide diphenol ether compound is # imgabs0, bifendate is dissolved in a solvent anhydrous tetrahydrofuran, lithium aluminum hydride is added, quenching, suction filtration, dichloromethane extraction, water addition quenching reaction and dichloromethane extraction are carried out, and the disulfide diphenol ether compound is obtained. Combining organic phases, removing residual moisture, and performing reduced pressure rotary evaporation recrystallization to obtain an intermediate 2; adding the intermediate 2 and potassium thioacetate into a solvent N, N-dimethylformamide for extraction, combining organic phases, and carrying out evaporation and concentration to remove the solvent so as to obtain a light intermediate 3; and dissolving the intermediate 3 with absolute methanol, adding sodium methoxide, stirring, extracting with ethyl acetate, and combining organic phases. The disulfide biphenyl compound prepared in the invention has good anti-inflammatory ability, can effectively reduce inflammation infiltration in tissues, improves the inflammation phenotype of an animal model, and can prevent and treat inflammatory skin diseases.

The invention relates to a dermatological or dermo-cosmetic composition in the form of a paraffin-free emulsion, particularly suitable for the treatment of inflammatory skin disorders, especially on sensitive or atopic skin. This composition comprises an aqueous phase containing at least one emollient selected from polyols, and an oily phase containing an oily emollient system comprising safflower oil at least 70% by weight and a second oily emollient.

The invention relates to the technical field of medicine, in particular to application of N-ethyl maleimide in inflammatory dermatosis, by adopting an LL-37-induced mouse rosacea model, experiments prove that NEM can directly and effectively inhibit inflammatory response by inhibiting glycerophospholipid metabolism and regulating expression of related genes such as keratinocytes and T lymphocytes, so that the inflammatory response is effectively inhibited, and the inflammatory response is inhibited. The compound can improve mouse rosacea-like rash, has no obvious cytotoxicity, can be used as a candidate compound, is used for developing a glycerophospholipid metabolism inhibitor, and is used for treating skin inflammatory diseases related to glycerophospholipid metabolism, such as rosacea and psoriasis. By utilizing multiple experimental means such as transcriptomics sequencing, histopathologic examination, reverse transcription real-time fluorescent quantitative PCR (RT-qPCR) and the like, it is proved for the first time that N-ethyl maleimide improves mouse rosacea by inhibiting glycerophospholipid metabolism.

The present invention is directed to compositions and methods for ameliorating symptoms associated with inflammatory skin disorders involving applying a synergistic blend of plant-based actives containing: (1) a synergistic blend of at least: (a) Calendula officinalis stem cell extract; (b) Symphytum officinale extract; (c) a biotech-derived Haberlea rhodopensis extract; and (d) Padina pavonica thallus extract; and (2) at least one skin protectant active ingredient.

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic / injured area).

The present invention relates to an inhibitor of CD74 protein activity or expression, for therapeutic use in the prevention and / or treatment of a chronic inflammatory disease selected from: chronic inflammatory rheumatic diseases, chronic inflammatory dermatoses, chronic inflammatory bowel diseases, and chronic inflammatory neurological diseases. In another aspect, the invention relates to an isolated anti-CD74 antibody or fragment thereof, comprising at least one CD74 receptor (CDR) having a sequence selected from SEQ ID NO. 1 to 5.

The present application relates to a use of a strain of the genus Cutibacterium, a culture of the strain, or a combination thereof for prevention, amelioration, and / or treatment of inflammatory skin diseases. A composition comprising a strain of the genus Cutibacterium, a culture of the strain, or a combination thereof does not show cytotoxicity, inhibits proliferation of immune cells that cause skin inflammation, suppresses immune responses, has an antibacterial effect against acne-causing bacteria, and promotes regeneration of skin cells, thereby exhibiting excellent preventive, ameliorating, and / or therapeutic effects of inflammatory skin diseases.

Disclosed is a substance which down-regulates the activity of a MAST gene, or the activity of a transcription or translation product of a MAST gene, for use in the prevent and / or treatment of an inflammatory skin condition in a mammalian subject.

Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.20 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous or non-aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, microemulsion, aerosol spray, non-aerosol spray, serum, solution, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and / or itchiness in the affected area compared to pre-treatment levels.

Provided herein are pharmaceutical formulations comprising an optionally 4-substituted phenylbutyrate for improved topical application. In some embodiments, the optionally 4-substituted phenylbutyrate is present at a concentration ranging from about 1-40% by weight. The present disclosure also provides methods of preparing said pharmaceutical formulations, as well as uses and methods of treating subjects affected by inflammatory skin disorder or skin-related disease with said pharmaceutical formulations.

The present invention is directed to compositions and methods for ameliorating symptoms associated with inflammatory skin disorders involving applying a synergistic blend of plant-based actives containing: (1) a synergistic blend of at least: (a) Calendula officinalis stem cell extract; (b) Symphytum officinale extract; (c) a biotech-derived Haberlea rhodopensis extract; and (d) Padina pavonica thallus extract; and (2) at least one skin protectant active ingredient.

Topical compositions including β-alanine and a transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8) agonist, such as menthol, are disclosed. Also disclosed are methods of decreasing skin inflammation or redness in a subject, and methods of decreasing frequency or duration of symptoms of inflammatory skin conditions, such as rosacea.

An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

The application discloses a traditional Chinese medicine composition for treating inflammatory dermatosis and a preparation method thereof, which is mainly prepared from the following Chinese herbal medicine raw materials in parts by weight: 10-15 parts of honeysuckle, 9-14 parts of forsythia, 10-20 parts of radix rehmanniae, 10-22 parts of cortex moutan, 10-20 parts of red peony root, 18-25 parts of kuh-seng, 15-25 parts of licorice, 12-18 parts of ophiopogon, 6-14 parts of radix codonopsis, 10-18 parts of hawthorn, 10-20 parts of radix scrophulariae, 8-18 parts of phellodendron, 30-45 parts of rhizoma coptidis, 8-15 parts of spina date seed, 8-14 parts of Uncaria, and 10-16 parts of borneol; the application can promote the generation of SCFAs, maintain the balance of intestinal microbial community, meanwhile, the SCFAs are also helpful to maintain the integrity and function of intestinal epithelial cells, thereby enhancing the intestinal barrier function, reducing the harmful substances and pathogens into blood, reducing the systemic inflammatory response, so that the skin inflammation can be directly inhibited, the skin recovery can be promoted, and the body obesity of patients with high-sugar diet can be effectively inhibited.

The invention discloses an AC (at) Mg / Ce-UiO nano particle, a preparation method thereof and application of the nano particle in medicines for treating inflammatory dermatosis, and belongs to the technical field of biological medicines. Adenylate cyclase (AC) is encapsulated in situ in an Mg / Ce-UiO metal organic framework designed by defect engineering, and a unique structure brings dual treatment strategies: the encapsulated AC catalyzes pro-inflammatory ATP to be converted into anti-inflammatory cAMP to restore balance; defective Mg / Ce-UiO simulates SOD (superoxide dismutase) and CAT (catalase) to remove excessive ROS. The nanoparticles can down-regulate the expression of various inflammatory factors and pruritus mediators, inhibit the excessive proliferation of keratinocytes and reduce the infiltration of immune memory T cells. Therefore, the effects of treating inflammatory skin disease skin lesion, remarkably relieving itching and preventing relapse are achieved. The preparation method is simple and easy for large-scale production. The invention introduces a reform mode to the treatment of inflammatory dermatosis, provides a curative strategy, establishes a multifunctional treatment framework, and is expected to be suitable for more extensive inflammation and autoimmune diseases.

The present invention is directed to compositions and methods for treating and managing symptoms associated with inflammatory skin disorders by applying a synergistic blend of plant-based actives containing at least: (a) Calendula officinalis stem cell extract; (b) Symphytum officinale extract; and (c) a biotech-derived Haberlea rhodopensis extract.

The invention discloses a compound tincture for treating inflammatory skin diseases and a preparation method of the compound tincture. The compound tincture is prepared from the following raw materials in percentage by weight: 0.02 to 0.06 percent of fluocinonide, 0.75 to 1.75 percent of chloramphenicol, 3 to 7 percent of salicylic acid, 0.05 to 0.15 percent of nano antibacterial particles, 1 to 3 percent of borneol, 6 to 10 percent of propylene glycol and the balance of water for injection. Compared with a compound fluocinonide tincture, the compound tincture has obvious effects in the aspects of relieving the severity of eczema, relieving the degree of pruritus and improving the quality of life in the clinical treatment process, and the total effective rate reaches 82-95.6%; compared with clindamycin hydrochloride gel, the total effective rate is high in the acne treatment period, the recurrence rate is low, and the untoward effect occurrence rate is not different; the relapse tincture disclosed by the invention has a remarkable and lasting curative effect on acne and eczema and a relatively small side effect, and is simple in preparation method, low in cost, remarkable in clinical curative effect and worthy of clinical popularization.

The invention relates to a pharmaceutical composition for treating inflammatory dermatosis and a preparation method thereof, and the preparation method comprises the following steps: 1) mixing oleyl alcohol, medium chain triglyceride, propylene glycol, hexadecanol and octadecanol, and heating to 65-75 DEG C to form an oil phase; adding pimerolimus and glyceryl monostearate and glyceryl distearate, and stirring to obtain an oil phase; 2) adding anhydrous citric acid, sodium hydroxide and benzyl alcohol into water, and heating to 65-75 DEG C for dissolving; adding cetostearyl sodium sulfate, and stirring to obtain a water phase; 3) pouring the oil phase into the water phase, maintaining the emulsification temperature at 65-75 DEG C, homogenizing and stirring to form an emulsion; and 4) filling and packaging. Wherein the mixed solution is subjected to homogenization treatment at the speed of 3000rpm for 10 minutes, homogenization is stopped, stirring is continued for 5 minutes at the speed of 25rpm, and the mixed solution is subjected to homogenization treatment at the speed of 3000rpm for 10 minutes again. The ratio of the humectant to the thickening agent in the pharmaceutical composition is creatively adjusted, so that the treatment efficiency of the ointment is greatly improved, and the user experience in the application process of the ointment is also remarkably improved.